Schroder Investment Management Group’s Akero Therapeutics AKRO Stock Holding History

Schroder Investment Management Group’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-215,372	Closed	-$10.3M	–	1146
2025 Q3	$10.3M	Buy	215,372 +65,941	+44%	+$3.19M	0.01%	658
2025 Q2	$7.97M	Buy	149,431 +32,824	+28%	+$1.49M	0.01%	679
2025 Q1	$4.98M	Buy	116,607 +90,992	+355%	+$3.86M	0.01%	756
2024 Q4	$716K	Sell	25,615 -158,817	-86%	-$4.81M	﹤0.01%	1055
2024 Q3	$5.21M	Sell	184,432 -62,031	-25%	-$1.62M	0.01%	780
2024 Q2	$5.78M	Buy	246,463 +75,507	+44%	+$1.61M	0.01%	752
2024 Q1	$4.32M	Buy	+170,956	New	+$4.11M	0.01%	807

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schroder Investment Management Group's AKRO Position: Q4 2025 in Review

Schroder Investment Management Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 215,372 shares — an estimated $10.3M sold.

Schroder Investment Management Group first reported a position in AKRO in Q1 2024 and held it in 7 quarters. The position peaked at $10.3M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Schroder Investment Management Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Schroder Investment Management Group sold 215,372 Akero Therapeutics shares in Q4 2025, an estimated $10.3M.
Schroder Investment Management Group first reported a position in Akero Therapeutics in Q1 2024 and held it in 7 quarters.
Schroder Investment Management Group's Akero Therapeutics position peaked at $10.3M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.